[go: up one dir, main page]

SG10201607909WA - Peptide nanoparticles and uses therefor - Google Patents

Peptide nanoparticles and uses therefor

Info

Publication number
SG10201607909WA
SG10201607909WA SG10201607909WA SG10201607909WA SG10201607909WA SG 10201607909W A SG10201607909W A SG 10201607909WA SG 10201607909W A SG10201607909W A SG 10201607909WA SG 10201607909W A SG10201607909W A SG 10201607909WA SG 10201607909W A SG10201607909W A SG 10201607909WA
Authority
SG
Singapore
Prior art keywords
uses therefor
peptide nanoparticles
nanoparticles
peptide
therefor
Prior art date
Application number
SG10201607909WA
Inventor
Jonathan Edelson
Timothy Kotyla
Original Assignee
Anterios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anterios Inc filed Critical Anterios Inc
Publication of SG10201607909WA publication Critical patent/SG10201607909WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/044—Suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
    • A61Q1/06—Lipsticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
SG10201607909WA 2006-12-01 2007-11-30 Peptide nanoparticles and uses therefor SG10201607909WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87220606P 2006-12-01 2006-12-01

Publications (1)

Publication Number Publication Date
SG10201607909WA true SG10201607909WA (en) 2016-11-29

Family

ID=40002812

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201607909WA SG10201607909WA (en) 2006-12-01 2007-11-30 Peptide nanoparticles and uses therefor
SG2012016762A SG179457A1 (en) 2006-12-01 2007-11-30 Peptide nanoparticles and uses therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012016762A SG179457A1 (en) 2006-12-01 2007-11-30 Peptide nanoparticles and uses therefor

Country Status (12)

Country Link
US (5) US20100172943A1 (en)
EP (1) EP2091516A2 (en)
JP (2) JP5292304B2 (en)
KR (2) KR101518077B1 (en)
CN (1) CN107080703A (en)
AU (1) AU2007353340A1 (en)
BR (1) BRPI0719732A2 (en)
CA (1) CA2671133C (en)
IL (2) IL199041A (en)
MX (1) MX2009005726A (en)
SG (2) SG10201607909WA (en)
WO (1) WO2008140594A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2007353340A1 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
BRPI0719756A2 (en) * 2006-12-01 2014-01-21 Anterios Inc Amphiphilic Nanoparticles
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US20110206739A1 (en) * 2008-03-28 2011-08-25 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
KR102080429B1 (en) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 Dermal delivery
CA2750559A1 (en) * 2009-02-05 2010-08-12 Digna Biotech, S.L. Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides
US20120021029A1 (en) * 2009-04-17 2012-01-26 Lipotec, S.A. Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
TR201905477T4 (en) 2011-01-24 2019-05-21 Anterios Inc Nano-particle compositions.
SG10201804552WA (en) * 2011-01-24 2018-07-30 Anterios Inc Nanoparticle compositions, formulations thereof, and uses therefor
US20120321579A1 (en) * 2011-01-24 2012-12-20 Anterios, Inc. Surfactant compositions
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
US20140242113A1 (en) * 2011-04-28 2014-08-28 Leonard P. Ruiz, JR. Liquid vaccine preparations
US8795643B1 (en) * 2011-04-29 2014-08-05 Michael Mark Anthony Method of preparing a hair treatment formulation comprising nanoparticles in solution and method of hair treatment utilizing a treatment formulation comprising nanoparticles in solution
US9078818B1 (en) * 2011-04-29 2015-07-14 Michael Mark Anthony Method of preparing a hair treatment formulation comprising nanoparticles in solution and method of hair treatment utilizing a treatment formulation comprising nanoparticles in solution
US9334306B2 (en) 2011-07-09 2016-05-10 The Regents Of The University Of California Leukemia stem cell targeting ligands and methods of use
EP2753358B1 (en) 2011-09-08 2018-01-24 The Regents of the University of California Fungal-specific metalloproteases and uses thereof
EP2861217B1 (en) * 2012-06-13 2017-09-06 The University Of Queensland Nanoemulsions
US10086035B2 (en) 2016-02-04 2018-10-02 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
US10583199B2 (en) * 2016-04-26 2020-03-10 Northwestern University Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs
KR102487144B1 (en) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 Transdermal delivery of large substances
CA3046037A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
EA201991003A1 (en) 2016-12-21 2019-12-30 Юнилевер Н.В. COMPOSITIONS FOR PERSONAL HYGIENE CONTAINING SMALL-SOLUBLE COMPOUNDS
EA038885B1 (en) 2016-12-21 2021-11-02 ЮНИЛЕВЕР АйПи ХОЛДИНГС Б.В. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
US11337908B2 (en) 2016-12-21 2022-05-24 Conopco, Inc. Personal care compositions with cystine
KR102087123B1 (en) * 2017-04-21 2020-03-10 유씨엘 주식회사 Nano-emulsion containing peptide and seaweeds extracts and cosmetic composition using the same
AU2018309058B2 (en) 2017-08-03 2023-02-16 ALASTIN Skincare, Inc. Compositions and methods for ameliorating skin laxity and body contour
WO2019054822A1 (en) * 2017-09-18 2019-03-21 애니젠 주식회사 Active substance-hexapeptide complex and cosmetic composition containing same
ES2726000A1 (en) 2018-03-28 2019-10-01 Infinitec Activos S L Gold nanoparticles and palmitoyl pentapeptide-4 (Machine-translation by Google Translate, not legally binding)
CN112165927B (en) * 2018-05-23 2024-01-30 联合利华知识产权控股有限公司 Nanoemulsion and preparation method thereof
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
US20220061315A1 (en) * 2020-08-26 2022-03-03 Simply Pure, LLC Persistent sanitizer
CN112587650A (en) * 2021-01-19 2021-04-02 中日友好医院(中日友好临床医学研究所) Short peptide and medical application of copper ion chelate thereof
GB2606739A (en) * 2021-05-19 2022-11-23 Landa Labs 2012 Ltd Method of preparing dermatological compositions
AU2023270264B2 (en) * 2021-05-19 2025-05-15 Landa Labs (2012) Ltd. Topical compositions and methods of preparing the same
WO2024013694A1 (en) * 2022-07-13 2024-01-18 Landa Labs (2012) Ltd. Compositions comprising surface modified globular nano-particles
WO2024110835A1 (en) * 2022-11-22 2024-05-30 Landa Labs (2012) Ltd. Use of nano-carriers for delivery of active agents
TWI826233B (en) * 2023-01-10 2023-12-11 台灣中油股份有限公司 Glucosamine derivative nanoparticle and preparation method and use thereof

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172149A (en) 1978-01-30 1979-10-23 Westwood Pharmaceuticals, Inc. Method for treating living skin exhibiting excessive sebum secretion
US4908154A (en) * 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US4533254A (en) * 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
JPS59102091U (en) 1982-12-24 1984-07-10 株式会社学習研究社 Game device with folding game board
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5651991A (en) * 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
IL88076A (en) 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
JPH0798740B2 (en) 1987-10-28 1995-10-25 日本新薬株式会社 Drug carrier
US5008110A (en) * 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
CH677886A5 (en) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
JP3765579B2 (en) 1990-08-24 2006-04-12 イーデーエーアー アーゲー Ultra-fine droplet preparation for active substance administration
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
AU664827B2 (en) * 1991-05-03 1995-12-07 Raisio Benecol Ltd. A substance for lowering high cholesterol level in serum and a method for preparing the same
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6939852B2 (en) 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
EP0572080B1 (en) 1992-05-29 1995-11-15 Quest International B.V. Aqueous perfume oil microemulsions
EP0571677A1 (en) 1992-05-29 1993-12-01 Unilever Plc Aqueous parfume oil microemulsions
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
WO1994023749A1 (en) 1993-04-19 1994-10-27 Institute For Advanced Skin Research Inc. Microemulsion preparation containing difficultly absorbable substance
JPH072689A (en) * 1993-04-19 1995-01-06 Advanced Sukin Res Kenkyusho:Kk Microemulsion pharmaceutical containing hardly absorbable substance
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
IT1261849B (en) 1993-09-02 1996-06-03 Avantgarde Spa MEDICAL DEVICE FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OR VERY LOW DOSAGE DRUGS, IN PARTICULAR HOMEOPATHIC DRUGS.
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5814324A (en) 1994-02-25 1998-09-29 Takeda Chemical Industries, Ltd. Injectable composition and a method of producing the same
JPH07285863A (en) 1994-02-25 1995-10-31 Takeda Chem Ind Ltd Composition for injection and its production
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2078190B1 (en) 1994-05-20 1996-08-01 Cusi Lab PROCEDURE FOR THE COATING OF GOTICLES OR PARTICLES OF NANOMETRIC SIZE.
EP0770422B1 (en) 1994-06-20 2002-09-04 Nippon Shinyaku Company, Limited Emulsion manufacturing method of emulsifier
US5672358A (en) 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
DE4440337A1 (en) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
FR2730932B1 (en) * 1995-02-27 1997-04-04 Oreal TRANSPARENT NANOEMULSION BASED ON FLUID NON-IONIC AMPHIPHILIC LIPIDS AND USE IN COSMETICS OR DERMOPHARMACY
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US20010051131A1 (en) * 1996-06-19 2001-12-13 Evan C. Unger Methods for delivering bioactive agents
FR2755854B1 (en) * 1996-11-15 1998-12-24 Oreal NANOEMULSION BASED ON NON-IONIC AND CATIONIC AMPHIPHILIC LIPIDS AND USES
DE69740139D1 (en) 1996-12-19 2011-04-14 Ibiden Co Ltd Multi-layer printed circuit board
FR2760970B1 (en) * 1997-03-18 2000-03-10 Oreal NANOEMULSIONS BASED ON NON-IONIC AMPHIPHILIC LIPIDS AND AMINO SILICONES AND USES
US5994414A (en) 1997-04-28 1999-11-30 Avon Products, Inc. Water-thin emulsion formed by high pressure homogenization process
GB9708066D0 (en) * 1997-04-22 1997-06-11 Woolcombers Group Plc Compositions and their use
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US20050025819A1 (en) * 1997-07-14 2005-02-03 Hayat Onyuksel Materials and methods for making improved micelle compositions
EP1475099B2 (en) * 1997-07-15 2014-04-09 The Regents of the University of Colorado Use of botulinum toxin to treat urinary incontinence
US6007856A (en) 1997-08-08 1999-12-28 The Procter & Gamble Company Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
EP1080720A4 (en) 1998-03-05 2002-06-05 Nippon Shinyaku Co Ltd Fat emulsions for inhalational administration
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
DE59914485D1 (en) * 1998-03-30 2007-10-18 Mibelle Ag Cosmetics Use of nanoemulsions to determine the biocompatibility of lipophilic substances in the cell culture test and suitable nanoemulsions
FI111513B (en) * 1998-05-06 2003-08-15 Raisio Benecol Oy New phytosterol and phytostanol fatty acid ester compositions, products containing the same and processes for preparing the same
US5932562A (en) * 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
US7220427B2 (en) * 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
FR2783169B1 (en) 1998-09-15 2001-11-02 Sederma Sa COSMETIC OR DERMOPHARMACEUTICAL USE OF PEPTIDES FOR HEALING AND FOR IMPROVING THE SKIN APPEARANCE DURING NATURAL OR ACCELERATED AGING (HELIODERMIA, POLLUTION)
US6242001B1 (en) * 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
DE19856897A1 (en) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic to suppress snoring noises
FR2787728B1 (en) * 1998-12-23 2001-01-26 Oreal NANOEMULSION BASED ON FATTY ESTERS OF PHOSPHORIC ACID, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS
HRP20010309B1 (en) 1998-12-23 2005-06-30 Idea Ag Improved formulation for topical non-invasive application in vivo
FR2788007B1 (en) * 1999-01-05 2001-02-09 Oreal NANOEMULSION BASED ON BLOCK COPOLYMERS OF ETHYLENE OXIDE AND PROPYLENE OXIDE, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
US6635676B2 (en) * 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
IL146567A0 (en) 1999-06-04 2002-07-25 Skyepharma Inc Oil-core particles containing a hydrophobic core material and hydrophobic drug and method for the preparation thereof
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
PL365423A1 (en) 1999-08-04 2005-01-10 Idea Ag Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6898427B1 (en) 1999-12-29 2005-05-24 Bellsouth Intellectual Property Corporation Method of coupling portable communications device to first network by way of second network
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
FR2804015B1 (en) * 2000-01-21 2005-12-23 Oreal NANEMULSION CONTAINING AMPHIPHILIC LIPIDS AND NONIONIC POLYMER AND USES THEREOF
ES2327901T3 (en) 2000-03-23 2009-11-05 Basf Catalysts Llc METHOD FOR PREPARING DISPERSIONS CONTAINING PHYSIOLOGICALLY ACTIVE INGREDIENTS AT HIGH PRESSURE / HIGH SHEAR.
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
FR2809112B1 (en) 2000-05-16 2004-05-07 Centre Nat Rech Scient MATERIALS BASED ON BIODEGRADABLE POLYMERS AND PREPARATION METHOD THEREOF
FR2809010B1 (en) 2000-05-22 2002-07-12 Oreal NANOEMULSION BASED ON ANIONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20020155084A1 (en) 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
FR2811561B1 (en) * 2000-07-13 2003-03-21 Oreal COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND / OR A CHEMICAL OR BIOLOGICAL PRECURSOR OR DERIVATIVE THEREOF, AND A METALLOPROTEINASE INHIBITOR
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6455058B1 (en) 2000-09-13 2002-09-24 Amitee Cosmetics, Inc. Composition and method for hair and scalp treatment
FR2816949B1 (en) 2000-11-17 2003-11-28 Centre Nat Rech Scient COPOLYMER WITH SEQUENCED STRUCTURE COMPOSED OF A SACCHARID SEGMENT LINKED TO AT LEAST ONE BIOERODABLE HYDROPHOBIC SEGMENT, AND CORRESPONDING PARTICLES
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
SI1345597T1 (en) * 2000-12-27 2007-12-31 Ares Trading Sa Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
FR2819427B1 (en) * 2001-01-18 2003-04-11 Oreal TRANSLUCENT NANOEMULSION, MANUFACTURING METHOD THEREOF AND USES THEREOF IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
FI20010115A0 (en) 2001-01-18 2001-01-18 Orion Corp A process for preparing nanoparticles
US20040048836A1 (en) * 2001-03-23 2004-03-11 Wilmott James M Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients
JP4444565B2 (en) 2001-03-30 2010-03-31 カラー アクセス，インコーポレイティド New nanoemulsion
KR100463167B1 (en) 2001-04-13 2004-12-23 주식회사 태평양 Percutaneous Controlled Releasing Material Using Nano-sized Polymeric Particles and External Application Agent Containing the Same
US7314624B2 (en) 2001-06-05 2008-01-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
KR100566911B1 (en) * 2001-06-25 2006-04-03 주식회사 삼양사 Anion group-containing amphiphilic block copolymers for drug carriers and complexes thereof with cationic drugs
WO2003011333A1 (en) * 2001-07-27 2003-02-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US7063860B2 (en) * 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US7235230B2 (en) * 2001-10-24 2007-06-26 Clariant Finance (Bvi) Limited Leave-on compositions for personal care
US20030077240A1 (en) * 2001-10-24 2003-04-24 Clariant International, Ltd. Use of high-purity phenylsilsesquioxane liquids for the preparation of cosmetic and pharmaceutical compositions
KR20040062602A (en) * 2001-10-30 2004-07-07 펜타팜아게 Dermopharmaceutically and cosmetically active oligopeptides
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
KR100441167B1 (en) * 2001-12-27 2004-07-21 씨제이 주식회사 Composition of microemulsion preconcentrate
US6861066B2 (en) * 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US6623780B1 (en) 2002-03-26 2003-09-23 Cargill, Inc. Aqueous dispersible sterol product
US20040115159A1 (en) * 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
EP1507514B1 (en) 2002-05-03 2007-02-14 PR Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
US7491403B2 (en) 2002-12-20 2009-02-17 Botulinum Toxin Research Associates Pharmaceutical botulinum toxin compositions
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040013687A1 (en) * 2002-05-31 2004-01-22 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20030224020A1 (en) 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
JP2005531606A (en) * 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド Nanoparticulate sterol formulations and sterol combinations
EP1531800B1 (en) * 2002-06-11 2011-06-08 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
US6996748B2 (en) * 2002-06-29 2006-02-07 Intel Corporation Handling faults associated with operation of guest software in the virtual-machine architecture
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
DE10238649A1 (en) * 2002-08-23 2004-03-11 Beiersdorf Ag Low-viscosity cosmetic or dermatological preparations of the oil-in-water type
AU2003270575A1 (en) * 2002-09-12 2004-04-30 3M Innovative Properties Company Fluoroelastomers having low temperature characteristics and solvent resistance
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
DE10258960A1 (en) * 2002-12-16 2004-07-01 Henkel Kgaa Nanoscale hydrogels against wrinkles, rough and dry skin
FR2849375B1 (en) * 2002-12-30 2006-10-20 Jean Noel Thorel COSMETIC COMPOSITIONS, FOR EXAMPLE FOR TREATING SKIN-INDUCED CUTANE AGING
CA2513064C (en) 2003-01-31 2009-11-10 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
WO2004071538A2 (en) * 2003-02-05 2004-08-26 Amphora Discovery Corporation Topical delivery of cosmetic agents
US20060153876A1 (en) * 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20040247623A1 (en) 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
AU2004273779B2 (en) 2003-06-04 2009-10-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
WO2004112821A1 (en) * 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. Remedies for diseases with hypermyotonia
CA2534471A1 (en) 2003-08-06 2005-02-17 Eisai Co., Ltd. Method and apparatus for producing ultrafine drug particles
AU2004263136A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
US7419996B2 (en) * 2003-08-13 2008-09-02 The University Of Houston Parenteral and oral formulations of benzimidazoles
CH715855B1 (en) * 2003-08-28 2020-08-14 Mibelle Ag Preparation consisting of at least two nanoemulsions.
EP1510206A1 (en) 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
JP2006199589A (en) 2003-09-03 2006-08-03 Ltt Bio-Pharma Co Ltd Nanoparticle containing physiologically active protein or peptide, method for producing the same and external preparation comprising the nanoparticle
DE602004027936D1 (en) * 2003-10-29 2010-08-12 Sonus Pharmaceutical Inc TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUND
KR101045658B1 (en) * 2003-11-17 2011-07-01 쎄데르마 Compositions Comprising Tetrapeptide and Tripeptide Mixtures
NO20035681D0 (en) 2003-12-18 2003-12-18 Amersham Health As Optical imaging of lung cancer
US20050136024A1 (en) * 2003-12-22 2005-06-23 Stockel Richard F. Dermatological compositions
EP1547674A1 (en) 2003-12-23 2005-06-29 MediGene Oncology GmbH Method for producing colloidal nanoparticles
US6974579B2 (en) 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
CA2554052C (en) 2004-01-23 2013-10-22 Camurus Ab Ternary non-lamellar lipid compositions of structure forming amphiphile, structure swelling amphiphile and dispersion stabilising amphiphile
AU2004316985A1 (en) 2004-02-23 2005-09-15 The Texas A & M University System Antioxidant compositions and methods of use thereof
DE102004009287A1 (en) 2004-02-26 2005-09-15 Institut Für Neue Materialien Gem. Gmbh Amphiphilic nanoparticles
ES2691498T3 (en) 2004-03-03 2018-11-27 Revance Therapeutics, Inc. Topical application and transdermal release of botulinum toxins
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
DE102004016710B4 (en) 2004-04-05 2020-11-19 Greppmayr GmbH Foot care formulation
EP1586336A1 (en) 2004-04-06 2005-10-19 JOHNSON & JOHNSON GmbH Compositions containing copper salts and soy products
TW200603843A (en) 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method
US20050249686A1 (en) 2004-04-27 2005-11-10 Francoise Pataut Cosmetic composition free of water comprising fatty acid esters, petrolatum oil and non-ionic polymers
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US7228259B2 (en) * 2004-06-30 2007-06-05 Lucent Technologies Inc. Method and apparatus for structure-preserving reduced-order modeling
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
CA2578250C (en) * 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
KR100623013B1 (en) 2004-09-04 2006-09-19 김영대 Nanoemulsion, its use and preparation method
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US20060084353A1 (en) * 2004-10-18 2006-04-20 Wong Tak K Reversible ball having hyper-elastic properties
KR20070086045A (en) 2004-11-12 2007-08-27 이데아 아게 Enlarged Surface Aggregates in the Treatment of Skin Conditions
CA2494473C (en) 2005-02-14 2007-06-26 Dpm Therapeutics Corp. Stabilized protein compositions for topical administration and methods of making same
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
ES2562494T3 (en) 2005-02-14 2016-03-04 Dpm Therapeutics Corporation Stabilized compositions for topical administration and methods for preparing them
EP1861112A4 (en) 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS
JP4444149B2 (en) 2005-03-30 2010-03-31 株式会社ナリス化粧品 Skin external preparation composed of ultra fine emulsion
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
EP1898947A2 (en) 2005-06-14 2008-03-19 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
JP5368793B2 (en) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル Compositions and methods for making and using nanoemulsions
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
WO2007035311A2 (en) 2005-09-16 2007-03-29 University Of Massachusetts Lowell Anti-oxidant synergy formulation nanoemulsions to treat cancer
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
DE102006046076A1 (en) * 2005-10-14 2007-04-19 Henkel Kgaa Cosmetic or dermatological topical composition contains oligopeptide derivative and apple extract, useful for treating e.g. wrinkles, creases and aging
CN101340884A (en) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 Method for treating hyperhidrosis
AU2006339325A1 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
PT3144013T (en) 2005-12-01 2019-02-07 Univ Massachusetts Lowell Botulinum nanoemulsions
CN101374860A (en) * 2005-12-23 2009-02-25 技术转让合伙人公司 Synthetic peptides useful as neurotransmitter secretion inhibitors and muscle relaxation inducers
US20070178121A1 (en) 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
EP1998742A2 (en) 2006-03-08 2008-12-10 Nuviance, INC. Transdermal drug delivery compositions and topical compositions for application on the skin
US20070237735A1 (en) * 2006-03-31 2007-10-11 Laboratoires Dermo-Cosmetik Inc. Anti-aging composition, kit and method of use
US20070253914A1 (en) * 2006-04-28 2007-11-01 Ha Robert B K Method of exfoliation
US20070274932A1 (en) * 2006-05-15 2007-11-29 The Procter & Gamble Company Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers
JP5697869B2 (en) * 2006-06-01 2015-04-08 セラピューティック ペプタイズ，インコーポレーテッド Polymer biosurfactant
WO2007149868A2 (en) 2006-06-20 2007-12-27 The Regents Of The University Of California Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles
WO2008038147A2 (en) 2006-07-05 2008-04-03 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
EP2073794A2 (en) 2006-11-14 2009-07-01 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
AU2007353340A1 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
BRPI0719756A2 (en) * 2006-12-01 2014-01-21 Anterios Inc Amphiphilic Nanoparticles
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
MX350501B (en) 2007-10-12 2017-09-07 Massachusetts Inst Technology Vaccine nanotechnology.
US20110206739A1 (en) 2008-03-28 2011-08-25 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
KR102080429B1 (en) 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 Dermal delivery
US20110206736A1 (en) 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
US20100137357A1 (en) * 2008-11-26 2010-06-03 Koleng John J Compositions and methods for hyperhidrosis
CA2750233A1 (en) 2009-01-28 2010-08-05 Nanobio Corporation Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
JP6131194B2 (en) 2011-01-24 2017-05-17 アンテリオス， インコーポレイテッド Empty nanoparticle composition and use thereof for treating dermatological symptoms
SG10201804552WA (en) 2011-01-24 2018-07-30 Anterios Inc Nanoparticle compositions, formulations thereof, and uses therefor

Also Published As

Publication number Publication date
MX2009005726A (en) 2009-09-28
SG179457A1 (en) 2012-04-27
CN101917959A (en) 2010-12-15
US10905637B2 (en) 2021-02-02
US20220175634A1 (en) 2022-06-09
BRPI0719732A2 (en) 2017-05-16
WO2008140594A2 (en) 2008-11-20
KR20150028308A (en) 2015-03-13
US9486409B2 (en) 2016-11-08
US20100172943A1 (en) 2010-07-08
JP2011502952A (en) 2011-01-27
CA2671133C (en) 2015-11-24
US20170079895A1 (en) 2017-03-23
KR20090098970A (en) 2009-09-18
CA2671133A1 (en) 2008-11-20
IL199041A (en) 2016-09-29
AU2007353340A1 (en) 2008-11-20
WO2008140594A3 (en) 2010-03-25
US20140234382A1 (en) 2014-08-21
KR101518077B1 (en) 2015-05-28
EP2091516A2 (en) 2009-08-26
IL247617A0 (en) 2016-11-30
CN107080703A (en) 2017-08-22
US20210308021A1 (en) 2021-10-07
JP5292304B2 (en) 2013-09-18
JP2013199487A (en) 2013-10-03

Similar Documents

Publication Publication Date Title
IL247617A0 (en) Peptide nanoparticles and uses therefor
ZA200810323B (en) Fkbp-l and uses thereof
LT2064327T (en) Dbait and uses thereof
ZA200809988B (en) Patch and uses thereof
ZA200807544B (en) Pseudoinfectious flavivirus and uses thereof
IL196397A0 (en) Prlr-specific antibody and uses thereof
IL194751A0 (en) Drugs and uses
GB0712670D0 (en) Isolated peptides and uses thereof
ZA200903906B (en) Carboranylporphyrins and uses thereof
EP1976864A4 (en) Novel peptide and use thereof
IL195525A0 (en) Replikin peptides and uses thereof
PL2046830T3 (en) Csf3r polypeptides and uses thereof
GB0604187D0 (en) Peptide and uses thereof
GB0616230D0 (en) Biomarkers and uses thereof
PL2032708T3 (en) Recombinant novirhabdoviruses and uses thereof
GB0823550D0 (en) Peptide tag and uses thereof
IL192800A0 (en) Fgf2-binding peptides and uses thereof
GB0617564D0 (en) Peptides and methods
GB0610059D0 (en) Uses and methods
HK1134782A (en) Peptide nanoparticles and uses therefor
PL378824A1 (en) Peptide and its application
GB0507475D0 (en) Peptide nanoparticles
GB0612873D0 (en) Isolated peptides and uses thereof
GB2444960B (en) Combined pseudoscope and hyperscope
GB0710813D0 (en) Peptides and uses thereof